Availability and rationality of fixed dose combinations available in Kaduna, Nigeria
Background: Fixed-dose drug combinations (FDCs), are combinations of two or more active drugs in a single dosage form. Despite the advantages obtained from the use of these agents, there is increasing evidence questioning the rationality of several FDCs found in pharmaceutical markets-especially those in developing countries like Nigeria.
Objectives: To describe the availability of FDCs in drug retailing outlets located in Kaduna Nigeria, and to assess FDC registration status and inclusion on national and international essential medicines lists (EMLs). Rationality of selected FDCs was also assessed.
Methods: A cross-sectional survey was carried out from June to September 2018 in 60 registered pharmacies and patent medicine shops selected through multi-stage sampling. A data collection form was used to obtain information on the generic names and strengths of the active ingredients of the FDCs, their country of manufacture and evidence of registration with the Nigerian drug regulatory agency. To assess rationality, a scoring rubric developed from earlier studies was used. Data collected was coded and entered into a Microsoft excel 2016 spreadsheet for analysis. Descriptive statistics (frequencies and percentages) were used to report the data collected.
Results: FDCs encountered included 74 oral tablets/capsules, 52 oral liquids and 23 topical semi solids. Majority of the available FDCs were registered by Nigerian drug regulatory agency (91.5%), although only 8.5% and 6.5% in total were included on the Nigerian EML and the WHO model list respectively. Of the 99 FDCs assessed for rationality, 58 (58.6%) were found to be rational. Irrational FDCs included drugs acting on the respiratory tract (29.3%), analgesics (26.8%) and anti-infectives (22%).
Conclusions: A wide variety of FDCs were available in the study area, even though not all of them were rational. There is an urgent need for policy makers within the country to develop better detailed guidelines for FDC registration.
Gautam CS, Saha L. Fixed dose drug combinations (FDCs): rational or irrational: a view point. Br J Clin Pharmacol. 2008;65(5):795-796. https://doi.org/10.1111/j.1365-2125.2007.03089.x
Wirtz VJ, Mol PG, Verdijk J, Vander Stichele RH, Taxis K. Use of antibacterial fixed-dose combinations in the private sector in eight Latin American Countries between 1999 and 2009. Trop Med Int Health. 2013;18(4):416-425. https://doi.org/10.1111/tmi.12068
Poudel A, Mohamed Ibrahim MI, Mishra P, Palaian S. Evaluation of the registration status of fixed-dose drug combinations in Nepal. J Pharm Health Serv Res. 2018;9(1):41-46. https://doi.org/10.1111/jphs.12205
Dalal K, Ganguly B, Gor A. Assessment of rationality of fixed dose combinations approved in CDSCO List. J Clin Diagn Res. 2016;10(4):FC05-FC08. https://doi.org/10.7860/JCDR/2016/17856.7691
Lokhandwala T, Smith N, Sternhufvud C, Sörstadius E, Lee WC, Mukherjee J. A retrospective study of persistence, adherence, and health economic outcomes of fixed-dose combination vs loose-dose combination of oral anti-diabetes drugs. J Med Econ. 2016;19(3):203-212. https://doi.org/10.3111/13696998.2015.1109518
Harris SB. The power of two: an update on fixed-dose combinations for type 2 diabetes. Expert Rev Clin Pharmacol. 2016;9(11):1453-1462. https://doi.org/10.1080/17512433.2016.1221758
Verma AA, Khuu W, Tadrous M, Gomes T, Mamdani MM. Fixed-dose combination antihypertensive medications, adherence, and clinical outcomes: A population-based retrospective cohort study. PLoS Med. 2018;15(6):e1002584. https://doi.org/10.1371/journal.pmed.1002584
ReAct, Why are fixed dose combinations of antibiotics generally not a good idea?. https://www.reactgroup.org/news-and-views/news-and-opinions/year-2018/why-are-fixed-dose-combinations-of-antibiotics-generally-not-a-good-idea/ (accessed Dec 28, 2018).
Ahmad A, Khan MU, Balkrishnan R. Fixed-dose combination antibiotics in India: global perspectives, Lancet Glob Health. 2016;4(8):e521. https://doi.org/10.1016/S2214-109X(16)30093-6
Poudel A, Mohamed Ibrahim MI, Mishra P, Palaian S. Assessment of the availability and rationality of unregistered fixed dose drug combinations in Nepal: a multicenter cross-sectional study. Glob Health Res Policy. 2017;2:14. https://doi.org/10.1186/s41256-017-0033-z
Shah S, Patel J, Desai M, Dikshit RK. Critical analysis of antimicrobial and respiratory fixed dose combinations available in Indian market. Int J Med Public Health. 2015;5(2):161-164. http://dx.doi.org/10.4103/2230-8598.153828
Roy V, Malhotra R, Tayal V, Bansal A, Gupta KS. Fixed-dose combinations for cough and common cold in India: an assessment of availability and rationality. Fundam Clin Pharmacol. 2011;25(2):258-266. https://doi.org/10.1111/j.1472-8206.2010.00840.x
McGettigan P, Roderick P, Mahajan R, Kadam A, Pollock AM. Use of Fixed Dose Combination (FDC) Drugs in India: Central Regulatory Approval and Sales of FDCs Containing Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Metformin, or Psychotropic Drugs. PLoS Med. 2015;12(5):e1001826. https://doi.org/10.1371/journal.pmed.1001826
McGettigan P, Roderick P, Kadam A, Pollock A. Threats to global antimicrobial resistance control: Centrally approved and unapproved antibiotic formulations sold in India. Br J Clin Pharmacol. 2019;85(1):59-70. https://doi.org/10.1111/bcp.13503
FMOH, Essential Medicines List Nigeria 6th Edition, Federal Ministry of Health Nigeria, Abuja, 2016.
WHO, WHO Model List of Essential Medicines-20th List, World Health Organization, 2017.
NPC, Population Distribution by Sex, State, LGA & Senatorial District, National Population Commission, Nigeria, Abuja, 2010.
KDSG, Demographics – Kaduna State Government, 2018. https://kdsg.gov.ng/demographics/ (accessed Dec 28, 2018).
PCN, List of Licensed Pharmacists and Licensed Pharmaceutical Premises, Pharmacists Council of Nigeria, Abuja, 2016.
Beyeler N, Liu J, Sieverding M. Systematic review of the role proprietary and patent medicine vendors in healthcare Provision in Nigeria. PLoS One. 2015;10(1):e0117165. https://doi.org/10.1371/journal.pone.0117165
Desai D, Wang J, Wen H, Li X, Timmins P. Formulation design, challenges, and development considerations for fixed dose combination (FDC) of oral solid dosage forms. Pharm Dev Technol. 2013;18(6):1265-1276. https://doi.org/10.3109/10837450.2012.660699
Hogerzeil HV. The concept of essential medicines: lessons for rich countries. BMJ. 2004;329(7475):1169-1172. https://doi.org/10.1136/bmj.329.7475.1169
Gupta AK, Arshad S, Poulter NR. Compliance, Safety, and Effectiveness of Fixed-Dose Combinations of Antihypertensive Agents. Hypertension. 2010 Feb;55(2):399-407. https://doi.org/10.1161/HYPERTENSIONAHA.109.139816
Williams SA, Buysman EK, Hulbert EM, Bergeson JG, Zhang B, Graham J. Hemoglobin A1c outcomes and health care resource use in type 2 diabetes mellitus patients treated with combination oral antidiabetic drugs through step therapy and loose-dose and fixed-dose combinations. Manag Care. 2012;21(7):40-48.
Kumar S, Goyal A, Gupta YK. Abuse of topical corticosteroids in India: Concerns and the way forward. J Pharmacol Pharmacother. 2016;7(1):1-5. https://doi.org/10.4103/0976-500X.179364
Pande S. Steroid containing fixed drug combinations banned by government of India: A big step towards dermatologic drug safety. Indian J Drugs Dermatol. 2016;2(1):1-2. https://doi.org/10.4103/2455-3972.184102
The authors hereby transfer, assign, or otherwise convey to Pharmacy Practice: (1) the right to grant permission to republish or reprint the stated material, in whole or in part, without a fee; (2) the right to print pr epublish copies for free distribution or sale; and (3) the right to republish the stated material in any format (electronic or printed). In addition, the undersigned affirms that the article described above has not previously been published, in whole or part, is not subject to copyright or other rights except by the author(s), and has not been submitted for publication elsewhere, except as communicated in writing to Pharmacy Practice with this document.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-NC-ND) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.